UroGen Pharma Ltd.
URGN
$29.80
-$1.53-4.88%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 34.68% | 37.68% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 34.68% | 37.68% | |||
| Cost of Revenue | 25.84% | 0.34% | |||
| Gross Profit | 35.52% | 42.74% | |||
| SG&A Expenses | 30.84% | 4.70% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 25.06% | 3.80% | |||
| Operating Income | -6.01% | 30.20% | |||
| Income Before Tax | -6.41% | 22.56% | |||
| Income Tax Expenses | -1,635.27% | 73.91% | |||
| Earnings from Continuing Operations | 10.58% | 20.94% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 10.58% | 20.94% | |||
| EBIT | -6.01% | 30.20% | |||
| EBITDA | -6.04% | 27.90% | |||
| EPS Basic | 12.27% | 22.83% | |||
| Normalized Basic EPS | -4.38% | 24.41% | |||
| EPS Diluted | 12.27% | 22.83% | |||
| Normalized Diluted EPS | -4.38% | 24.41% | |||
| Average Basic Shares Outstanding | 1.93% | 2.44% | |||
| Average Diluted Shares Outstanding | 1.93% | 2.44% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||